Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > New Startup AeonClad Biomedical Applies Patented Coatings Technology AeonCoat™ to the Drug Delivery and Medical Devices Markets

Abstract:
Specialty coatings company, AeonClad Coatings LLC, has announced the launch of a newly formed subsidiary, AeonClad Biomedical LLC. The new company will focus on biomedical applications utilizing the AeonCoat™ Technology. AeonCoat is a dry coating technology that offers a single-step, solvent-free process producing conformal films. The technology enables custom tailored coatings allowing for improved dissolution of poorly water soluble drugs, as well as modified or sustained release. Coatings can also display functional groups used for secondary covalent coupling of biological materials or for targeted drug delivery.

New Startup AeonClad Biomedical Applies Patented Coatings Technology AeonCoat™ to the Drug Delivery and Medical Devices Markets

Austin, TX | Posted on January 20th, 2009

Key Markets and Business Development

By concentrating on drug delivery and medical devices, AeonClad Biomedical is positioned to meet key market needs. The nanotechnology-based drug delivery market is expected to garner $700-$800 billion revenues by 20151. Expectations are that the market will be driven by the expanding horizon of therapeutic applications. Venture capital investments in nanotechnology drug delivery companies have been increasing and have provided further positive spin to the market growth.

Medical device coatings is the most rapidly expanding sector of the $213-billion global medical device market. These coatings increase the functionality, longevity and cost-effectiveness of medical devices. Global sales generated by coatings and surface-treatment processes used on medical devices is expected to grow significantly. Predictions are that the market will reach more than $5.31 billion by 2010, an average annual growth rate of 12.4%; and that the medical device coatings sector will grow to $7.5 billion by 20142.

AeonCoat Technology

Drug Delivery Applications

AeonCoat Technology will be used to coat and encapsulate drugs or active pharmaceutical ingredients (API's). The AeonCoat process yields many advantages in drug delivery due to its ability to individually coat particles on both the micro and nano scales. AeonClad Biomedical strives to overcome technical challenges in drug delivery such as agglomeration and poor drug solubility.

With the ability to individually coat particles, AeonClad Biomedical has the capability to:

* Decrease agglomeration of drug particles, increasing drug bioavailability
* Improve dissolution and bioavailability of poorly soluble drugs, enabling decreased excipient loading and increased potency of API's

AeonClad Biomedical will also specialize in customizing drug release profiles by uniquely tailoring coatings to allow for modified or sustained release at the micro or nanoparticle level. In addition, the technology can also be used to functionalize particles for targeted delivery.

Medical Devices

AeonClad Biomedical customizes medical device coatings to fit customer specifications. The AeonCoat Technology enables custom coatings varying in functionality, chemical composition, and thickness. AeonClad Biomedical specializes in lubricious coatings, coatings to increase cell adhesion, non-fouling coatings, or functional coatings for attachment of biological materials.

####

About AeonClad Coatings LLC
AeonClad Coatings LLC is a specialty coatings company founded on the pioneering research of Dr. Richard Timmons and his team. The AeonCoat Technology offers a single-step, solvent-free process producing conformable films. The technology also enables functionalization of surfaces to produce antimicrobial, anti-thrombogenic, lubricious, and biocompatible interfaces. AeonClad Coatings is funded and managed by life sciences venture firm, Emergent Technologies, Inc.

About AeonClad Biomedical

An AeonClad Coatings LLC subsidiary, AeonClad Biomedical LLC utilizes the AeonCoat™ technology, previously licensed by AeonClad Coatings from Dr. Richard Timmons at the University of Texas at Arlington. AeonClad Biomedical is focused on applications for the drug delivery and medical device coatings industries. For more information, visit the company website at www.aeoncladbiomedical.com

About Emergent Technologies, Inc.

Emergent Technologies Inc. (ETI), founded in 1989 by Thomas A. Harlan, is a unique life sciences venture firm that forms and manages companies and funds that commercialize groundbreaking institutional and university-based technologies. ETI is a turnkey solution for converting university science into high return ventures. ETI works with regional economic development groups and universities to capitalize on what the firm describes as invention capital. In addition to the traditional venture capital approach of raising and investing funds, ETI drives the selection and expansion of each technology assets unique to their region. ETI is pioneering a unique business approach to investment in intellectual property, the key asset to most technology-based start-up companies. For more information, visit the company website www.etibio.com

1. "Investing in Drug Delivery Technologies: Fighting Patent Expiries," Frost & Sullivan, September 18, 2008.

2. “Medical Device Coatings,” BCC Research, November 12, 2008.

For more information, please click here

Contacts:
Nsight Public Relations
Sandra Oak
321-591-1508

Copyright © Business Wire 2009

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

Nanomedicine

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

Announcements

Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

Patents/IP/Tech Transfer/Licensing

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Bruker Awarded Fourth PeakForce Tapping Patent: AFM Mode Uniquely Combines Highest Resolution Imaging and Material Property Mapping July 22nd, 2014

Rice's silicon oxide memories catch manufacturers' eye: Use of porous silicon oxide reduces forming voltage, improves manufacturability July 10th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE